Betaxolol is a β1-adrenergic receptor antagonist (IC50 = 6 μM) used for its neuroprotective effects on retinal neurons; it attenuates NMDA-induced neurotoxicity when β-adrenergic receptor agonists are ineffective; it blocks glutamate-induced LDH release (at 10 μM); it prevents hypoxia-induced LDH release in cortical tissues (at 100 μM); in vivo, it reduces calretinin and ChAT immunoreactivity changes and prevents b-wave reduction in rat models of retinal ischemia-reperfusion injury; it partially counteracts alterations induced by NMDA and oxygen-glucose deprivation.